Literature DB >> 15656697

The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

David G Le Couteur1, Robin Fraser, Sarah Hilmer, Laurent P Rivory, Allan J McLean.   

Abstract

The fenestrated sinusoidal endothelium ('liver sieve') and space of Disse in the healthy liver do not impede the transfer of most substrates, including drugs and oxygen, from the sinusoidal lumen to the hepatocyte. Plasma components transfer freely in both directions through the endothelial fenestrations and into the space of Disse. The endothelium is attenuated, there is no basement membrane and there is minimum collagen in the space of Disse, thus minimising any barriers to substrate diffusion. Both cirrhosis and aging are associated with marked structural changes in the sinusoidal endothelium and space of Disse that are likely to influence bulk plasma transfer into the space of Disse, and diffusion through the endothelium and space of Disse. These changes, termed capillarisation and pseudocapillarisation in cirrhosis and aging, respectively, impede the transfer of various substrates. Capillarisation is associated with exclusion of albumin, protein-bound drugs and macromolecules from the space of Disse, and the progressive transformation of flow-limited to barrier-limited distribution of some substrates. There is evidence that the sinusoidal changes in cirrhosis and aging contribute to hepatocyte hypoxia, thus providing a mechanism for the apparent differential reduction of oxygen-dependent phase I metabolic pathways in these conditions. Structural change and subsequent dysfunction of the liver sieve warrant consideration as a significant factor in the impairment of overall substrate handling and hepatic drug metabolism in cirrhosis and aging.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15656697     DOI: 10.2165/00003088-200544020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  84 in total

1.  Aging and the response of the isolated perfused rat liver to vasoactive drugs.

Authors:  D Le Couteur; L P Rivory; M S Roberts; S M Pond
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

2.  Filtration of chylomicrons by the liver may influence cholesterol metabolism and atherosclerosis.

Authors:  R Fraser; A G Bosanquet; W A Day
Journal:  Atherosclerosis       Date:  1978-02       Impact factor: 5.162

3.  Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease.

Authors:  D J Morgan; A J McLean
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

4.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 5.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

6.  Hepatic circulation in cirrhosis.

Authors:  P M Huet; J P Villeneuve; G Pomier-Layrargues; D Marleau
Journal:  Clin Gastroenterol       Date:  1985-01

7.  Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.

Authors:  D G Le Couteur; H Hickey; P J Harvey; J Gready; A J McLean
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

8.  Effect of cirrhosis on sulphation by the isolated perfused rat liver.

Authors:  E F Choo; P W Angus; D J Morgan
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

9.  Uptake of materials by the intact liver. The exchange of glucose across the cell membranes.

Authors:  C A Goresky; B E Nadeau
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

10.  31P and 1H NMR spectroscopic studies of liver extracts of carbon tetrachloride-treated rats.

Authors:  P J Harvey; J E Gready; H M Hickey; D G Le Couteur; A J McLean
Journal:  NMR Biomed       Date:  1999-10       Impact factor: 4.044

View more
  40 in total

1.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 2.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Caloric restriction reduces age-related pseudocapillarization of the hepatic sinusoid.

Authors:  Hamish A Jamieson; Sarah N Hilmer; Victoria C Cogger; Alessandra Warren; Rajkumar Cheluvappa; Darrell R Abernethy; Arthur V Everitt; Robin Fraser; Rafael de Cabo; David G Le Couteur
Journal:  Exp Gerontol       Date:  2007-01-03       Impact factor: 4.032

4.  Age-related changes in the hepatic microcirculation in mice.

Authors:  Yoshiya Ito; Karen K Sørensen; Nancy W Bethea; Dmitri Svistounov; Margaret K McCuskey; Bård H Smedsrød; Robert S McCuskey
Journal:  Exp Gerontol       Date:  2007-04-29       Impact factor: 4.032

Review 5.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

6.  Effects of old age on vascular complexity and dispersion of the hepatic sinusoidal network.

Authors:  Alessandra Warren; Slawomir Chaberek; Kazimierz Ostrowski; Victoria C Cogger; Sarah N Hilmer; Robert S McCuskey; Robin Fraser; David G Le Couteur
Journal:  Microcirculation       Date:  2008-04       Impact factor: 2.628

7.  Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity.

Authors:  Summer M Raines; Oliver C Richards; Lindsay R Schneider; Kathryn L Schueler; Mary E Rabaglia; Angie T Oler; Donald S Stapleton; Guillem Genové; John A Dawson; Christer Betsholtz; Alan D Attie
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-06-14       Impact factor: 4.310

8.  Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.

Authors:  Masaru Hirano; Dan Meyers; GangaRaju Golla; Parasar Pal; Pascale Pinot; TsuHan Lin; Tapan Majumdar; Sam Rebello; Gangadhar Sunkara; Jin Chen
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 9.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

10.  Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations.

Authors:  Carmen C Franz; Carole Hildbrand; Christa Born; Sabin Egger; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.